CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to BGNE

Tislelizumab (BGB-A317)

Phase 2
BeiGene, Ltd. (BGNE)

Phase 2

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Nov '26
BGNEPhase 2

Tislelizumab (BGB-A317) Phase 2 Est. Readout

Tislelizumab (BGB-A317)
Nov 2026~
CT.gov
00%
Competitive Landscape

0 competitors in MSI-H/dMMR Solid Tumors

View Full Landscape
Drug Information

Target Indication

MSI-H/dMMR Solid Tumors

Clinical Trial

NCT03736889

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.